Skip to main content
HCPCS Q0234 · Level II · Part B drug

Q0234: tocilizumab-bavi, HCPCS Level II drug code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for Q0234

Billing unit
1 MG
Inj, tocilizumab-bavi, 1mg
ASP payment limit
$6.327
October 2026; +0.0% vs July 2026
Practitioner MUE
none published
CMS publishes no MUE for this code
OPPS status
SI L
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS Q0234 is the Level II code for Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $6.327 per billing unit, up 0.0% from July 2026. Under OPPS it carries status indicator L. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. Other HCPCS codes whose descriptor names tocilizumab: Q5133 (biosimilar tocilizumab-bavi (Tofidence) from Organon LLC); Q5135 (biosimilar tocilizumab-aazg (Tyenne) from Fresenius Kabi USA, LLC); Q5156 (biosimilar tocilizumab-anoh (Avtozma) from Celltrion USA, Inc); Q0237 (tocilizumab-anoh); Q0238 (tocilizumab-aazg); Q0249 (for hospitalized adults and pediatric patients 2 years and older with COVID-19; the code whose CMS descriptor names no specific product). No current Billing and Coding Article lists Q0234, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for Q0234 at $6.327 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $6.327 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for Q0234
QuarterPayment limitPerCoinsurance
October 2026$6.3271 MG20%
July 2026$6.3271 MG—
CMS note: See COVID-19 vaccine pricing webpage for payment effective dates

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk lists no NDC for Q0234. Report the NDC from the product label and confirm the units conversion from the HCPCS descriptor (Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg).

Medically Unlikely Edits (MUE)

CMS does not publish an MUE for Q0234 in the 2026 Q4 tables. Some MUE values are confidential and applied without publication, so unit limits can still deny; document the dose and the units calculation on every claim.

MUE for Q0234 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists Q0234 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check Q0234 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

Q0234 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists Q0234 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, Q0234 carries status indicator L. The OPPS status indicator reference explains how status L is paid.

Common denials for Q0234 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for Q0234

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS Q0234

What does HCPCS code Q0234 describe?

Q0234 is defined by CMS as "Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is Q0234 a CPT code?

No. Q0234 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as tocilizumab-bavi; CPT codes are five-character codes maintained by the AMA. On a Part B claim Q0234 reports the drug itself in 1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for Q0234 in October 2026?

The ASP-based payment limit is $6.327 per 1 MG, with 20% beneficiary coinsurance. The July 2026 limit was $6.327. Commercial payers use their own fee schedules.

Does Q0234 have NCCI bundling edits?

No active practitioner PTP pairs list Q0234 as a column-1 or column-2 code in the v323r0 release.

Q0234 vs Q5133: what is the difference?

Both are HCPCS Level II codes whose descriptor names tocilizumab-bavi. What sets Q5133 apart: biosimilar tocilizumab-bavi (Tofidence) from Organon LLC. Q0234 is billed per 1 mg, limit $6.327; Q5133 is billed per 1 mg, limit $4.706, MUE 1200. Report the code whose descriptor matches the product and setting in the record.

Q0234 vs Q5135: what is the difference?

Both are HCPCS Level II codes whose descriptor names tocilizumab. What sets Q5135 apart: biosimilar tocilizumab-aazg (Tyenne) from Fresenius Kabi USA, LLC. Q0234 is billed per 1 mg, limit $6.327; Q5135 is billed per 1 mg, limit $4.37, MUE 1200. Report the code whose descriptor matches the product and setting in the record.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.